A study led by scientists at Queen Mary University of London reports that adding a viral protein called NoV B2 to self-amplifying RNA (saRNA) reduces the cellular defenses that normally limit the technology, while preserving saRNA's ability to stimulate the immune system.

The paper, published in Nature Communications and titled "Tuning intracellular immunity by Nodamura virus B2 protein enhances self-amplifying RNA activity," found that the protein — already known to suppress RNA interference — reduced the extent to which cells restrict saRNA. The result: the modified saRNA produced far more of the intended protein in both stem cells and regular cells.

The problem NoV B2 addresses

The work targets a specific and well-documented bottleneck. During the self-replication process, saRNA generates double-stranded RNA. That double-stranded RNA triggers the host cell's antiviral defenses, making the saRNA less stable, less able to replicate, and less able to instruct cells to produce the protein that trains the immune system. This mechanism has limited the effectiveness of saRNA vaccines and has hampered their application in gene therapies, cancer immunotherapies, and protein replacement therapies.

The context is familiar to anyone managing an RNA platform portfolio. mRNA vaccines rose to prominence during the Covid-19 pandemic, and since then researchers have pursued saRNA, which replicates within host cells. The stated goal of the field is to develop vaccines and therapies that provide longer-lasting protection at lower doses, and that remain safe and affordable.

What was measured

The reported results come from cell-based experiments. The researchers measured protein output from saRNA constructs with and without NoV B2 in two cell contexts — stem cells and regular cells — and found higher protein production when the B2 protein was present. The study also reports that the protein preserved saRNA's immunostimulatory function.

What the study has not yet shown, on the evidence presented, is efficacy in animals or humans. The authors themselves frame the clinical implications as conditional. "Our findings identify a strategy to overcome a fundamental barrier limiting self-amplifying vaccines," said Pierre Maillard, PhD, senior lecturer in antiviral immunity at Queen Mary University of London and one of the study's authors. "If this translates successfully in vivo, it could open new possibilities for vaccine design as well for gene therapies and cancer treatment."

That caveat matters for anyone weighing the finding against other dose-sparing strategies in the saRNA space. Intracellular immune evasion is one of several levers under investigation, and this study's data are cellular rather than organismal.

Practical stakes

For R&D managers in RNA therapeutics, the significance is straightforward. If the approach does translate in vivo, it could allow effective saRNA vaccines at lower doses, which in turn would support broader and faster rollout than current saRNA candidates have achieved. Lower required doses have direct implications for manufacturing cost, fill-finish capacity, and program economics across vaccine and gene therapy pipelines.

The study's authors indicate the development could help scientists build saRNA vaccines that work at lower doses and could be deployed further and faster than has been possible to date.

The next step, implied by the authors' own framing, is in vivo validation: whether the cellular gains observed with NoV B2 hold up in animal models will determine whether the approach becomes a practical design option for saRNA programs.